Angiogenesis-associated Sequence Variants Relative to Breast Cancer Recurrence and Survival

Overview

Journal Cancer Causes Control

Specialties Oncology
Public Health

Date 2010 Jun 24

PMID 20571871

Citations 12

Authors

LaCreis R Kidd

Guy N Brock

Tiva T VanCleave

Marnita L Benford

Nicole A Lavender

Traci L Kruer

James L Wittliff

Affiliations

Soon will be listed here.

Abstract

Introduction: Breast cancer (BrCA) risk stratification using clinico-pathological biomarkers helps improve disease prognosis prediction. However, disease recurrence rates remain unfavorable and individualized clinical management strategies are needed. Consequently, we evaluated the influence of 14 sequence variants detected in IL-10, TGF-β1, VEGF, and their associated receptors as effective predictors of BrCA clinical outcomes.

Methods: Tumor DNA samples collected from 441 BrCA patients were genotyped using TaqMan-PCR. Most selected targets alter cytokine serum/plasma levels or signaling pathways. Relationships between genetic profiles and recurrence as well as disease-related mortality were evaluated using cumulative incidence curves and competing risk regression models.

Results: The VEGF(-2578)C allele was associated with a 1.3- to 1.6-fold increase in BrCA recurrence (HR(trend) = 1.28; 95% CI = 0.96-1.72) and disease-related mortality (HR(trend) = 1.56; 95% CI = 0.93-2.56). Although this marker was marginally significant relative to BrCA outcomes, there were substantial gains in the 5- and 8-year predictive accuracy compared to standard prognostic indicators. Among ER(+)/PR(+) status patients, there was a significant impact of the VEGF(-2578)CC genotype on disease recurrence and predictive accuracy.

Conclusions: Our findings suggest inheritance of the VEGF(-2578)C allele could serve as an independent prognostic indicator of BrCA prognosis. The VEGF(-2578) marker may have clinical implications among a subset of ER(+)/PR(+) patients with an aggressive phenotype. Because the VEGF(-2578)C allele is linked to high VEGF expression, this cytokine is a potential prognostic and targeted clinical management tool.

Citing Articles

Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor A (VEGF-A) expressions in Ethiopian female breast cancer and their association with histopathologic features.

Addisu S, Bekele A, Seifu D, Assefa M, Gemechu T, Hoenerhoff M PLoS One. 2024; 19(10):e0308411.

PMID: 39405290 PMC: 11478813. DOI: 10.1371/journal.pone.0308411.

Advances in non-invasive imaging for dermatofibrosarcoma protuberans: A review.

Algarin Y, Pulumati A, Tan J, Zeitouni N Australas J Dermatol. 2024; 65(8):610-620.

PMID: 39361531 PMC: 11629142. DOI: 10.1111/ajd.14366.

The Relation of VEGFA, VEGFR2, VEGI, and HIF1A Genetic Variants and Their Serum Protein Levels with Breast Cancer in Egyptian Patients.

Abdelgalil A, Monir R, Elmetwally M, Ghattas M, Bazeed F, Mesbah N Biochem Genet. 2023; 62(1):547-573.

PMID: 37392242 DOI: 10.1007/s10528-023-10419-4.

Diagnosis and differential diagnosis of dermatofibrosarcoma protuberans: Utility of high-resolution dynamic contrast-enhanced (DCE) MRI.

Yu Q, Zhu Y, Huang R, Li Y, Song L, Zhang X Skin Res Technol. 2022; 28(5):651-663.

PMID: 35639715 PMC: 9907642. DOI: 10.1111/srt.13164.

Association of VEGF haplotypes with breast cancer risk in North-West Indians.

Sambyal V, Guleria K, Kapahi R, Manjari M, Sudan M, Uppal M BMC Med Genomics. 2021; 14(1):209.

PMID: 34429108 PMC: 8386001. DOI: 10.1186/s12920-021-01060-4.

References

Turner D, Williams D, Sankaran D, Lazarus M, Sinnott P, Hutchinson I . An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet. 1997; 24(1):1-8. DOI: 10.1111/j.1365-2370.1997.tb00001.x. View

Linderholm B, Grankvist K, Wilking N, Johansson M, Tavelin B, Henriksson R . Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J Clin Oncol. 2000; 18(7):1423-31. DOI: 10.1200/JCO.2000.18.7.1423. View

Dunning A, Ellis P, McBride S, Kirschenlohr H, Healey C, Kemp P . A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res. 2003; 63(10):2610-5. View

Coradini D, Biganzoli E, Pellizzaro C, Veneroni S, Oriana S, Ambrogi F . Vascular endothelial growth factor in node-positive breast cancer patients treated with adjuvant tamoxifen. Br J Cancer. 2003; 89(2):268-70. PMC: 2394273. DOI: 10.1038/sj.bjc.6601060. View

Stearns M, Fudge K, Garcia F, Wang M . IL-10 inhibition of human prostate PC-3 ML cell metastases in SCID mice: IL-10 stimulation of TIMP-1 and inhibition of MMP-2/MMP-9 expression. Invasion Metastasis. 1997; 17(2):62-74. View

Jacobs E, Feigelson H, Bain E, Brady K, Rodriguez C, Stevens V . Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort. Breast Cancer Res. 2006; 8(2):R22. PMC: 1557725. DOI: 10.1186/bcr1400. View

Ryden L, Stendahl M, Jonsson H, Emdin S, Bengtsson N, Landberg G . Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response. Breast Cancer Res Treat. 2005; 89(2):135-43. DOI: 10.1007/s10549-004-1655-7. View

Guidi A, Schnitt S, Fischer L, Tognazzi K, Harris J, Dvorak H . Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer. 1997; 80(10):1945-53. DOI: 10.1002/(sici)1097-0142(19971115)80:10<1945::aid-cncr11>3.0.co;2-y. View

Tan W . Novel agents and targets in managing patients with metastatic prostate cancer. Cancer Control. 2006; 13(3):194-8. DOI: 10.1177/107327480601300306. View

10.

Sfar S, Hassen E, Saad H, Mosbah F, Chouchane L . Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome. Cytokine. 2006; 35(1-2):21-8. DOI: 10.1016/j.cyto.2006.07.003. View

11.

Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher T . A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer. 2003; 106(4):468-471. DOI: 10.1002/ijc.11238. View

12.

Kinoshita J, Kitamura K, Kabashima A, Saeki H, Tanaka S, Sugimachi K . Clinical significance of vascular endothelial growth factor-C (VEGF-C) in breast cancer. Breast Cancer Res Treat. 2001; 66(2):159-64. DOI: 10.1023/a:1010692132669. View

13.

Kushlinskii N, Gershtein E . Role of vascular endothelial growth factor during breast cancer. Bull Exp Biol Med. 2002; 133(6):521-8. DOI: 10.1023/a:1020259702427. View

14.

Nakamura M, Abe Y, Tokunaga T . Pathological significance of vascular endothelial growth factor A isoform expression in human cancer. Pathol Int. 2002; 52(5-6):331-9. DOI: 10.1046/j.1440-1827.2002.01367.x. View

15.

Gasparini G, Toi M, Gion M, Verderio P, Dittadi R, Hanatani M . Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst. 1997; 89(2):139-47. DOI: 10.1093/jnci/89.2.139. View

16.

Foekens J, Peters H, Grebenchtchikov N, Look M, Meijer-van Gelder M, Geurts-Moespot A . High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res. 2001; 61(14):5407-14. View

17.

Lambrechts D, Storkebaum E, Morimoto M, Del-Favero J, Desmet F, Marklund S . VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet. 2003; 34(4):383-94. DOI: 10.1038/ng1211. View

18.

Dummer W, Becker J, Schwaaf A, Leverkus M, Moll T, Brocker E . Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res. 1995; 5(1):67-8. DOI: 10.1097/00008390-199502000-00008. View

19.

J van t Veer L, Dai H, van de Vijver M, He Y, Hart A, Mao M . Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; 415(6871):530-6. DOI: 10.1038/415530a. View

20.

Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E . A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res. 2001; 37(6):443-8. DOI: 10.1159/000054076. View